{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:55:07Z","timestamp":1792162507808,"version":"4.4.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health & Welfare","award":["RS-2025-25467624"],"award-info":[{"award-number":["RS-2025-25467624"]}]},{"name":"Ministry of Health & Welfare","award":["MD-PhD\/Medical Scientist Training Program"],"award-info":[{"award-number":["MD-PhD\/Medical Scientist Training Program"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR070713"],"award-info":[{"award-number":["RS-2022-NR070713"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and ICT and Ministry of Health & Welfare","award":["RS-2024-00467177"],"award-info":[{"award-number":["RS-2024-00467177"]}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["2024-22-0165"],"award-info":[{"award-number":["2024-22-0165"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SNUH Kun-hee Lee Child Cancer and Rare Disease Project","award":["22B-000-0101"],"award-info":[{"award-number":["22B-000-0101"]}]},{"name":"Ministry of Education (MOE) and the Seoul Metropolitan Government","award":["2025-RISE-01-022-05"],"award-info":[{"award-number":["2025-RISE-01-022-05"]}]},{"name":"Lee Youn Jae","award":["Yonsei Fellow Program"],"award-info":[{"award-number":["Yonsei Fellow Program"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Biol"],"DOI":"10.1186\/s13059-026-03977-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:24:35Z","timestamp":1770081875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors"],"prefix":"10.1186","volume":"27","author":[{"given":"Hyeong-Cheol","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonseung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyongbum Henry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"1","key":"3977_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00449-x","volume":"7","author":"A Shreenivas","year":"2023","unstructured":"Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023;7(1):101. https:\/\/doi.org\/10.1038\/s41698-023-00449-x.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"3977_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","volume":"4","author":"JL Schneider","year":"2023","unstructured":"Schneider JL, Lin JJ, Shaw AT. ALK-positive lung cancer: a moving target. Nat Cancer. 2023;4(3):330\u201343. https:\/\/doi.org\/10.1038\/s43018-023-00515-0.","journal-title":"Nat Cancer"},{"issue":"7153","key":"3977_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136. https:\/\/doi.org\/10.1038\/nature05945.","journal-title":"Nature"},{"issue":"2","key":"3977_CR4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3892\/ol.2018.9856","volume":"17","author":"Z Cao","year":"2019","unstructured":"Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou WB. Anaplastic lymphoma kinase fusions: roles in cancer and therapeutic perspectives. Oncol Lett. 2019;17(2):2020\u201330. https:\/\/doi.org\/10.3892\/ol.2018.9856.","journal-title":"Oncol Lett"},{"issue":"5151","key":"3977_CR5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science. 1994;263(5151):1281\u20134. https:\/\/doi.org\/10.1126\/science.8122112.","journal-title":"Science"},{"issue":"2","key":"3977_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/gcc.10267","volume":"38","author":"M Debiec-Rychter","year":"2003","unstructured":"Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P. Alk-atic fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003;38(2):187\u201390. https:\/\/doi.org\/10.1002\/gcc.10267.","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"3977_CR7","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","volume":"7","author":"E Lin","year":"2009","unstructured":"Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009;7(9):1466\u201376. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0522.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"3977_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1056\/NEJMc2101264","volume":"385","author":"A Bagchi","year":"2021","unstructured":"Bagchi A, Orr BA, Campagne O, Dhanda S, Nair S, Tran Q, et al. Lorlatinib in a child with ALK-fusion-positive high-grade glioma. N Engl J Med. 2021;385(8):761\u20133. https:\/\/doi.org\/10.1056\/NEJMc2101264.","journal-title":"N Engl J Med"},{"issue":"14","key":"3977_CR9","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-21-3521","volume":"29","author":"AF Blandin","year":"2023","unstructured":"Blandin AF, Giglio R, Graham MS, Garcia G, Malinowski S, Woods JK, et al. ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Clin Cancer Res. 2023;29(14):2651\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3521.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"3977_CR10","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006. https:\/\/doi.org\/10.1001\/jama.2014.3741.","journal-title":"JAMA"},{"key":"3977_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00419","volume":"10","author":"N Hirai","year":"2020","unstructured":"Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y. Monomerization of ALK fusion proteins as a therapeutic strategy in ALK-rearranged non-small cell lung cancers. Front Oncol. 2020;10:419. https:\/\/doi.org\/10.3389\/fonc.2020.00419.","journal-title":"Front Oncol"},{"key":"3977_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9090118","author":"SR Sabir","year":"2017","unstructured":"Sabir SR, Yeoh S, Jackson G, Bayliss R. Eml4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel). 2017. https:\/\/doi.org\/10.3390\/cancers9090118.","journal-title":"Cancers (Basel)"},{"issue":"21","key":"3977_CR13","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK -positive non\u2013small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1810171.","journal-title":"N Engl J Med"},{"issue":"9","key":"3977_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795.","journal-title":"N Engl J Med"},{"issue":"21","key":"3977_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2027187.","journal-title":"N Engl J Med"},{"issue":"25","key":"3977_CR16","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394. https:\/\/doi.org\/10.1056\/NEJMoa1214886.","journal-title":"N Engl J Med"},{"issue":"23","key":"3977_CR17","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1408440.","journal-title":"N Engl J Med"},{"issue":"10072","key":"3977_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(17)30123-X.","journal-title":"Lancet"},{"issue":"2","key":"3977_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7(2):137\u201355. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1123.","journal-title":"Cancer Discov"},{"issue":"18","key":"3977_CR20","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","volume":"363","author":"YL Choi","year":"2010","unstructured":"Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1007478.","journal-title":"N Engl J Med"},{"issue":"22","key":"3977_CR21","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-19-1436","volume":"25","author":"I Dagogo-Jack","year":"2019","unstructured":"Dagogo-Jack I, Rooney M, Lin JJ, Nagy RJ, Yeap BY, Hubbeling H, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019;25(22):6662\u201370. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1436.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3977_CR22","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0596.","journal-title":"Cancer Discov"},{"issue":"18","key":"3977_CR23","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1073\/pnas.1019559108","volume":"108","author":"R Katayama","year":"2011","unstructured":"Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535\u201340. https:\/\/doi.org\/10.1073\/pnas.1019559108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3977_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000358","volume":"9","author":"G Toyokawa","year":"2014","unstructured":"Toyokawa G, Hirai F, Inamasu E, Yoshida T, Nosaki K, Takenaka T, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J Thorac Oncol. 2014;9(12):e86. https:\/\/doi.org\/10.1097\/JTO.0000000000000358.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3977_CR25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res. 2020;26(11):2535\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3906.","journal-title":"Clin Cancer Res"},{"issue":"120","key":"3977_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003316","volume":"4","author":"R Katayama","year":"2012","unstructured":"Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3003316.","journal-title":"Sci Transl Med"},{"issue":"2","key":"3977_CR27","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.cllc.2021.06.011","volume":"23","author":"B Koopman","year":"2022","unstructured":"Koopman B, Groen HJM, Schuuring E, Hiltermann TJN, Timens W, den Dunnen WFA, et al. Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature. Clin Lung Cancer. 2022;23(2):e104\u201315. https:\/\/doi.org\/10.1016\/j.cllc.2021.06.011.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"3977_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin Cancer Res. 2020;26(1):242\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1104.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3977_CR29","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714\u201329. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1256.","journal-title":"Cancer Discov"},{"issue":"4","key":"3977_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"3977_CR31","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-21-0221","volume":"20","author":"BW Murray","year":"2021","unstructured":"Murray BW, Zhai D, Deng W, Zhang X, Ung J, Nguyen V, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1499\u2013507. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0221.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3977_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100015","volume":"1","author":"SI Ou","year":"2020","unstructured":"Ou SI, Zhu VW, Nagasaka M. Catalog of 5\u2019 fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res Rep. 2020;1(1):100015. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100015.","journal-title":"JTO Clin Res Rep"},{"issue":"22","key":"3977_CR33","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen PJ, Hussmann JA, Yan J, Knipping F, Ravisankar P, Chen PF, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635-52 e29. https:\/\/doi.org\/10.1016\/j.cell.2021.09.018.","journal-title":"Cell"},{"issue":"9","key":"3977_CR34","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41587-024-02465-z","volume":"43","author":"Y Kim","year":"2024","unstructured":"Kim Y, Oh HC, Lee S, Kim HH. Saturation profiling of drug-resistant genetic variants using prime editing. Nat Biotechnol. 2024;43(9):1471\u201384. https:\/\/doi.org\/10.1038\/s41587-024-02465-z.","journal-title":"Nat Biotechnol"},{"issue":"8008","key":"3977_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","volume":"628","author":"J Yan","year":"2024","unstructured":"Yan J, Oyler-Castrillo P, Ravisankar P, Ward CC, Levesque S, Jing Y, et al. Improving prime editing with an endogenous small RNA-binding protein. Nature. 2024;628(8008):639\u201347. https:\/\/doi.org\/10.1038\/s41586-024-07259-6.","journal-title":"Nature"},{"issue":"5","key":"3977_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","volume":"25","author":"C Voena","year":"2025","unstructured":"Voena C, Ambrogio C, Iannelli F, Chiarle R. ALK in cancer: from function to therapeutic targeting. Nat Rev Cancer. 2025;25(5):359\u201378. https:\/\/doi.org\/10.1038\/s41568-025-00797-9.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3977_CR37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson JW, Randolph PB, Shen SP, Everette KA, Chen PJ, Anzalone AV, et al. Engineered pegRNAs improve prime editing efficiency. Nat Biotechnol. 2022;40(3):402\u201310. https:\/\/doi.org\/10.1038\/s41587-021-01039-7.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"3977_CR38","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.cell.2023.03.034","volume":"186","author":"G Yu","year":"2023","unstructured":"Yu G, Kim HK, Park J, Kwak H, Cheong Y, Kim D, et al. Prediction of efficiencies for diverse prime editing systems in multiple cell types. Cell. 2023;186(10):2256-72 e23. https:\/\/doi.org\/10.1016\/j.cell.2023.03.034.","journal-title":"Cell"},{"issue":"1","key":"3977_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28752-9","volume":"8","author":"J Li","year":"2018","unstructured":"Li J, Huang Y, Wu M, Wu C, Li X, Bao J. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. Sci Rep. 2018;8(1):10664. https:\/\/doi.org\/10.1038\/s41598-018-28752-9.","journal-title":"Sci Rep"},{"issue":"1","key":"3977_CR40","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114296","volume":"14","author":"Y Lu","year":"2022","unstructured":"Lu Y, Fan Z, Zhu SJ, Huang X, Zhuang Z, Li Y, et al. A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol Med. 2022;14(1):e14296. https:\/\/doi.org\/10.15252\/emmm.202114296.","journal-title":"EMBO Mol Med"},{"key":"3977_CR41","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.25","volume":"7","author":"D Poei","year":"2024","unstructured":"Poei D, Ali S, Ye S, Hsu R. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist. 2024;7:20. https:\/\/doi.org\/10.20517\/cdr.2024.25.","journal-title":"Cancer Drug Resist"},{"key":"3977_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.compbiolchem.2016.10.005","volume":"65","author":"Z Ni","year":"2016","unstructured":"Ni Z, Wang X, Zhang T, Jin RZ. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer. Comput Biol Chem. 2016;65:54\u201360. https:\/\/doi.org\/10.1016\/j.compbiolchem.2016.10.005.","journal-title":"Comput Biol Chem"},{"issue":"4708","key":"3977_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1126\/science.3892686","volume":"229","author":"SK Burley","year":"1985","unstructured":"Burley SK, Petsko GA. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science. 1985;229(4708):23\u20138. https:\/\/doi.org\/10.1126\/science.3892686.","journal-title":"Science"},{"issue":"1","key":"3977_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21396-w","volume":"12","author":"H Mizuta","year":"2021","unstructured":"Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nat Commun. 2021;12(1):1261. https:\/\/doi.org\/10.1038\/s41467-021-21396-w.","journal-title":"Nat Commun"},{"issue":"16","key":"3977_CR45","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1200\/JCO.18.02236","volume":"37","author":"AT Shaw","year":"2019","unstructured":"Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, et al. Alk resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol. 2019;37(16):1370\u20139. https:\/\/doi.org\/10.1200\/JCO.18.02236.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3977_CR46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","volume":"3","author":"A Shiba-Ishii","year":"2022","unstructured":"Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022;3(6):710\u201322. https:\/\/doi.org\/10.1038\/s43018-022-00399-6.","journal-title":"Nat Cancer"},{"issue":"11","key":"3977_CR47","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/s41588-024-01948-8","volume":"56","author":"MA Coelho","year":"2024","unstructured":"Coelho MA, Strauss ME, Watterson A, Cooper S, Bhosle S, Illuzzi G, et al. Base editing screens define the genetic landscape of cancer drug resistance mechanisms. Nat Genet. 2024;56(11):2479\u201392. https:\/\/doi.org\/10.1038\/s41588-024-01948-8.","journal-title":"Nat Genet"},{"issue":"7675","key":"3977_CR48","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nature24037","volume":"550","author":"X Kong","year":"2017","unstructured":"Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, et al. Cancer drug addiction is relayed by an ERK2-dependent phenotype switch. Nature. 2017;550(7675):270\u20134. https:\/\/doi.org\/10.1038\/nature24037.","journal-title":"Nature"},{"issue":"3","key":"3977_CR49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.lungcan.2011.11.007","volume":"76","author":"K Suda","year":"2012","unstructured":"Suda K, Tomizawa K, Osada H, Maehara Y, Yatabe Y, Sekido Y, et al. Conversion from the \u201concogene addiction\u201d to \u201cdrug addiction\u201d by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer. 2012;76(3):292\u20139. https:\/\/doi.org\/10.1016\/j.lungcan.2011.11.007.","journal-title":"Lung Cancer"},{"key":"3977_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01531-4","author":"Y Jung","year":"2025","unstructured":"Jung Y, Yu G, Oh HC, Lee JH, Jeon E, Bae J, et al. Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing. Nat Biomed Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01531-4.","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"3977_CR51","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.molonc.2013.08.001","volume":"7","author":"HR Kim","year":"2013","unstructured":"Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol. 2013;7(6):1093\u2013102. https:\/\/doi.org\/10.1016\/j.molonc.2013.08.001.","journal-title":"Mol Oncol"},{"issue":"35","key":"3977_CR52","doi-asserted-by":"publisher","first-page":"58771","DOI":"10.18632\/oncotarget.17680","volume":"8","author":"SH Choi","year":"2017","unstructured":"Choi SH, Kim DH, Choi YJ, Kim SY, Lee JE, Sung KJ, et al. Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement. Oncotarget. 2017;8(35):58771\u201380. https:\/\/doi.org\/10.18632\/oncotarget.17680.","journal-title":"Oncotarget"},{"key":"3977_CR53","unstructured":"DepMap, Broad (2025). DepMap Public 25Q3. Dataset. depmap.org [Internet]."},{"issue":"8043","key":"3977_CR54","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-024-08167-5","volume":"636","author":"J Jee","year":"2024","unstructured":"Jee J, Fong C, Pichotta K, Tran TN, Luthra A, Waters M, et al. Automated real-world data integration improves cancer outcome prediction. Nature. 2024;636(8043):728\u201336. https:\/\/doi.org\/10.1038\/s41586-024-08167-5.","journal-title":"Nature"},{"issue":"5","key":"3977_CR55","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","volume":"26","author":"SC Bresler","year":"2014","unstructured":"Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26(5):682\u201394. https:\/\/doi.org\/10.1016\/j.ccell.2014.09.019.","journal-title":"Cancer Cell"},{"issue":"8016","key":"3977_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630(8016):493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w.","journal-title":"Nature"},{"issue":"108","key":"3977_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002950","volume":"3","author":"SC Bresler","year":"2011","unstructured":"Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med. 2011;3(108):108ra14. https:\/\/doi.org\/10.1126\/scitranslmed.3002950.","journal-title":"Sci Transl Med"},{"issue":"28","key":"3977_CR58","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1038\/onc.2015.434","volume":"35","author":"DN Debruyne","year":"2016","unstructured":"Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, Cheung NK, et al. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene. 2016;35(28):3681\u201391. https:\/\/doi.org\/10.1038\/onc.2015.434.","journal-title":"Oncogene"},{"issue":"48","key":"3977_CR59","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.18632\/oncotarget.27119","volume":"10","author":"S Durand","year":"2019","unstructured":"Durand S, Pierre-Eugene C, Mirabeau O, Louis-Brennetot C, Combaret V, Colmet-Daage L, et al. Alk mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. Oncotarget. 2019;10(48):4937\u201350. https:\/\/doi.org\/10.18632\/oncotarget.27119.","journal-title":"Oncotarget"},{"issue":"13","key":"3977_CR60","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","volume":"27","author":"JH Foster","year":"2021","unstructured":"Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, et al. Activity of crizotinib in patients with ALK-aberrant relapsed\/refractory neuroblastoma: a children\u2019s oncology group study (ADVL0912). Clin Cancer Res. 2021;27(13):3543\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4224.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3977_CR61","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","volume":"14","author":"YP Mosse","year":"2013","unstructured":"Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a children\u2019s oncology group phase 1 consortium study. Lancet Oncol. 2013;14(6):472\u201380. https:\/\/doi.org\/10.1016\/S1470-2045(13)70095-0.","journal-title":"Lancet Oncol"},{"issue":"24","key":"3977_CR62","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","volume":"70","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010;70(24):10038\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2956.","journal-title":"Cancer Res"},{"key":"3977_CR63","doi-asserted-by":"publisher","first-page":"e2200547","DOI":"10.1200\/PO.22.00547","volume":"7","author":"N Gene-Olaciregui","year":"2023","unstructured":"Gene-Olaciregui N, Perez-Somarriba M, Santa-Maria V, Cruz O, Gomez-Gonzalez S, Castaneda A, et al. Clinical and Molecular Evolution of an ALK-Driven Infant-Type Hemispheric Glioma Treated Sequentially With Second- and Third-Generation Anaplastic Lymphoma Kinase Inhibitors. JCO Precis Oncol. 2023;7:e2200547. https:\/\/doi.org\/10.1200\/PO.22.00547.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"3977_CR64","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783\u20134. https:\/\/doi.org\/10.1038\/nmeth.3047.","journal-title":"Nat Methods"},{"issue":"1","key":"3977_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41551-024-01233-3","volume":"9","author":"AA Sousa","year":"2025","unstructured":"Sousa AA, Hemez C, Lei L, Traore S, Kulhankova K, Newby GA, et al. Systematic optimization of prime editing for the efficient functional correction of CFTR F508del in human airway epithelial cells. Nat Biomed Eng. 2025;9(1):7\u201321. https:\/\/doi.org\/10.1038\/s41551-024-01233-3.","journal-title":"Nat Biomed Eng"},{"key":"3977_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0846-3","volume":"16","author":"Y Dang","year":"2015","unstructured":"Dang Y, Jia G, Choi J, Ma H, Anaya E, Ye C, et al. Optimizing sgrna structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol. 2015;16:280. https:\/\/doi.org\/10.1186\/s13059-015-0846-3.","journal-title":"Genome Biol"},{"issue":"4","key":"3977_CR67","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","volume":"184","author":"R Cuella-Martin","year":"2021","unstructured":"Cuella-Martin R, Hayward SB, Fan X, Chen X, Huang JW, Taglialatela A, et al. Functional interrogation of DNA damage response variants with base editing screens. Cell. 2021;184(4):1081-97 e19. https:\/\/doi.org\/10.1016\/j.cell.2021.01.041.","journal-title":"Cell"},{"key":"3977_CR68","doi-asserted-by":"crossref","unstructured":"Oh HC, Han Y, Chang Y, Kim H. A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors. Datasets. Sequence Read Archive. 2026. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1272298.","DOI":"10.1186\/s13059-026-03977-4"},{"key":"3977_CR69","unstructured":"Oh HC, Han Y, Chang Y, Kim H. Functional atlas of ALK kinase domain variants. Github. 2026. https:\/\/github.com\/po99044\/ALK."},{"key":"3977_CR70","doi-asserted-by":"publisher","unstructured":"Oh HC, Han Y, Chang Y, Kim H. Functional atlas of ALK kinase domain variants (v1.0.0). Zenodo. 2026. https:\/\/doi.org\/10.5281\/zenodo.18333259.","DOI":"10.5281\/zenodo.18333259"}],"container-title":["Genome Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13059-026-03977-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13059-026-03977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13059-026-03977-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T11:24:14Z","timestamp":1772623454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13059-026-03977-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3977"],"URL":"https:\/\/doi.org\/10.1186\/s13059-026-03977-4","relation":{},"ISSN":["1474-760X"],"issn-type":[{"value":"1474-760X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Based on the findings of this study, Yonsei University has filed a patent listing H.C.O., Y.H., Y. C., and H.H.K. as inventors. H.H.K is the founder and an employee of cisionMed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}